Overview
- A federal jury in California found Apple infringed Masimo patents through the Apple Watch’s workout mode and heart‑rate notification features.
- Apple said it will appeal, arguing the patent at issue expired in 2022 and relates to older patient‑monitoring technology.
- The U.S. International Trade Commission launched a review of Apple’s redesigned pulse‑oximetry feature that could result in a renewed import ban.
- Apple previously disabled blood‑oxygen readings in U.S. models after a 2023 ITC ruling, then reintroduced a redesigned version in August 2025 with customs approval.
- Masimo called the verdict an important victory for protecting its innovations, as its wider patent and trade‑secret claims against Apple continue across venues.